{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:36Z","timestamp":1786118976869,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1097\/mop.0b013e328318c529","type":"journal-article","created":{"date-parts":[[2008,11,12]],"date-time":"2008-11-12T03:12:23Z","timestamp":1226459543000},"page":"628-633","source":"Crossref","is-referenced-by-count":13,"title":["Tuberous sclerosis complex: disease modifiers and treatments"],"prefix":"10.1097","volume":"20","author":[{"given":"Kit Sing","family":"Au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210206","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/302381","article-title":"Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis","volume":"64","author":"Jones","year":"1999","journal-title":"Am J Hum Genet"},{"key":"R2-3-20210206","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/jmg.2003.012757","article-title":"Genotype and psychological phenotype in tuberous sclerosis","volume":"41","author":"Lewis","year":"2004","journal-title":"J Med Genet"},{"key":"R3-3-20210206","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R4-3-20210206","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","article-title":"Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex","volume":"13","author":"Sancak","year":"2005","journal-title":"Eur J Hum Genet"},{"key":"R5-3-20210206","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/GIM.0b013e31803068c7","article-title":"Genotype\/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States","volume":"9","author":"Au","year":"2007","journal-title":"Genet Med"},{"key":"R6-3-20210206","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.mrrev.2008.01.001","article-title":"The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners","volume":"658","author":"Rosner","year":"2008","journal-title":"Mut Res"},{"key":"R7-3-20210206","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"R8-3-20210206","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/jmg.30.1.41","article-title":"Variability of expression in tuberous sclerosis","volume":"30","author":"Northrup","year":"1993","journal-title":"J Med Genet"},{"key":"R9-3-20210206","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1177\/0883073807307093","article-title":"Intrafamilial phenotypic variability in tuberous sclerosis complex","volume":"22","author":"Lyczkowski","year":"2007","journal-title":"J Child Neurol"},{"key":"R10-3-20210206","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/01.WNL.0000113745.58425.EF","article-title":"Monozygotic twins with tuberous sclerosis discordant for the severity of developmental deficits","volume":"62","author":"Humphrey","year":"2004","journal-title":"Neurology"},{"key":"R11-3-20210206","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.mrfmmm.2003.12.023","article-title":"The transcriptional profile of kidney in Tsc2 heterozygous mutant Long Evans (Eker) rats compared to wild-type","volume":"549","author":"Sen","year":"2004","journal-title":"Mut Res"},{"key":"R12-3-20210206","doi-asserted-by":"crossref","first-page":"8286","DOI":"10.1073\/pnas.0712268105","article-title":"Phospholipase D1 is an effector of Rheb in the mTOR pathway","volume":"105","author":"Sun","year":"2008","journal-title":"PNAS"},{"key":"R13-3-20210206","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1086\/342718","article-title":"Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients","volume":"71","author":"Dabora","year":"2002","journal-title":"Am J Hum Genet"},{"key":"R14-3-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2370.1999.00122.x","article-title":"In vitro production of IFN-g correlates with CA repeat polymorphism in the human IFN-g gene","volume":"26","author":"Pravica","year":"1999","journal-title":"Eur J Immunogenet"},{"key":"R15-3-20210206","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4049\/jimmunol.164.1.231","article-title":"IFN-g-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells","volume":"164","author":"Lee","year":"2000","journal-title":"J Immunol"},{"key":"R16-3-20210206","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nm1001-1159","article-title":"Adoptive tumor therapy with T lymphocytes enriched through an IFN-g capture assay","volume":"7","author":"Becker","year":"2001","journal-title":"Nat Med"},{"key":"R17-3-20210206","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1349-7006.2003.tb01410.x","article-title":"Renal carcinogenesis: genotype, phenotype and dramatype","volume":"94","author":"Hino","year":"2003","journal-title":"Cancer Sci"},{"key":"R18-3-20210206","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/geno.2001.6654","article-title":"Genetic identification of a locus, Mot1, that affects renal tumor size in rat","volume":"78","author":"Yeung","year":"2001","journal-title":"Genomics"},{"key":"R19-3-20210206","first-page":"75","article-title":"Presence of a modifier gene(s) affecting early renal carcinogenesis in the Tsc2 mutant (Eker) rat model","volume":"24","author":"Kikuchi","year":"2004","journal-title":"Int J Oncol"},{"key":"R20-3-20210206","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1471-4159.2006.04277.x","article-title":"Serotonin and epilepsy","volume":"100","author":"Bagdy","year":"2007","journal-title":"J Neurochem"},{"key":"R21-3-20210206","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/sj.tpj.6500315","article-title":"Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2c receptor isoforms","volume":"5","author":"Fentress","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"R22-3-20210206","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.mp.4001357","article-title":"Modification of human 5-HT2C receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution","volume":"9","author":"Okada","year":"2004","journal-title":"Mol Psychiatry"},{"key":"R23-3-20210206","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1055\/s-2004-832685","article-title":"Neuroimaging and 5-HT2C receptor polymorphism: a HMPAO-SPECT study in healthy male probands using mCPP-challenge of the 5-HT2C receptor","volume":"37","author":"Kuhn","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R24-3-20210206","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors","volume":"374","author":"Tecott","year":"1995","journal-title":"Nature"},{"key":"R25-3-20210206","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1749-6632.1998.tb10175.x","article-title":"Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice","volume":"861","author":"Heisler","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"R26-3-20210206","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568026053386980","article-title":"Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs","volume":"5","author":"Isaac","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"R27-3-20210206","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"R28-3-20210206","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"R29-3-20210206","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1056\/NEJMc072500","article-title":"Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis","volume":"358","author":"Davies","year":"2008","journal-title":"N Engl J Med"},{"key":"R30-3-20210206","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1378\/chest.07-0898","article-title":"Lymphangioleiomyomatosis: a clinical update","volume":"133","author":"McCormack","year":"2008","journal-title":"Chest"},{"key":"R31-3-20210206","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","article-title":"Effects of rapamycin in the Eker rat model of tuberous sclerosis complex","volume":"57","author":"Kenerson","year":"2005","journal-title":"Pediatr Res"},{"key":"R32-3-20210206","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/gcc.20357","article-title":"Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex","volume":"45","author":"Lee","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"R33-3-20210206","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2210-7-14","article-title":"Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779","volume":"7","author":"Messina","year":"2007","journal-title":"BMC Pharmacol"},{"key":"R34-3-20210206","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"key":"R35-3-20210206","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J Neurosci"},{"key":"R36-3-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-5945-8-1","article-title":"Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model","volume":"8","author":"Rauktys","year":"2008","journal-title":"BMC Dermatol"},{"key":"R37-3-20210206","first-page":"3469","article-title":"Tuberous sclerosis-associated neoplasms express activated p42\/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth","volume":"9","author":"Govindarajan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R38-3-20210206","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1067\/mjd.2002.120530","article-title":"Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms","volume":"46","author":"Arbiser","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R39-3-20210206","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0002-9440(10)64237-X","article-title":"Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis","volume":"161","author":"Arbiser","year":"2002","journal-title":"Am J Pathol"},{"key":"R40-3-20210206","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbapap.2007.10.003","article-title":"Targeting phosphoinositide 3-kinase: moving towards therapy","volume":"1784","author":"Marone","year":"2008","journal-title":"Biochim Biophys Acta"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOP.0b013e328318c529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:13:09Z","timestamp":1786036389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008480-200812000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0b013e328318c529","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}